title: [Tranexamic acid therapy decreases mortality of traumatic hemorrhagic shock].
abstract: The CRASH 2, a randomized, double-blind, controlled trial, that enrolled 20,211 adult trauma patients, has shown that the administration of tranexamic acid significantly reduces all-cause mortality and that specifically associated with severe blood loss as well. We consider it a significant therapeutic advance, because, for the first time, a drug has been demonstrated to safely diminish mortality due to traumatic bleeding shock. On the basis of these results, and the high rate of death due to traumatic bleeding, we suggest that tranexamic acid should be considered for compassionate use in bleeding trauma patients prior to its definitive approval for this medical condition.
authors.affiliation: Cuidados Críticos y Urgencias, Hospital Universitario Virgen del Rocío, Sevilla, España. angeles.munoz.sspa@juntadeandalucia.es
authors.forename: A
authors.initials: A
authors.lastname: Muñoz-Sánchez
authors.forename: F
authors.initials: F
authors.lastname: Murillo-Cabezas
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012771:Shock, Hemorrhagic / Q000188:drug therapy* / Q000401:mortality*; D012774:Shock, Traumatic / Q000188:drug therapy* / Q000401:mortality*; D014148:Tranexamic Acid / Q000627:therapeutic use*
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid